Reviewer’s report

Title: Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine

Version: 1 Date: 12 December 2010

Reviewer: Cosimo Prantera

Reviewer’s report:

The result is based on studies on Mezavant employed in inducing remission of mild to moderate UC active phases.

Major compulsory revision:

1-The only reported article, which has given the results of one-year remission maintenance with Mezavant, was an extension study of the two acute phases trials.

This was an open study that enrolled only those patients who responded to the therapy and, consequently, cannot be considered a true maintenance trial.

The only maintenance study that has compared the 1-year success of Mezavant with Asacol, was published 1 year ago in AP&T and was already presented as abstract at 2008 DDW.

This lack could be a limit, and the data of that study should be incorporated in the present Markov model.

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I have been involved and I have received fees for participating in studies with this molecule.